Literature DB >> 25553130

IgM Myeloma or Waldenstrom's Macroglobulinemia Is the Big Question?

Vijaya Raj Bhatt1, Srujitha Murukutla1, Muniba Naqi1, Shradha Pant2, Shiksha Kedia1, Terenig Terjanian1.   

Abstract

ABSTRACT: Although critical from therapeutic and prognostic perspectives, differentiating IgM Myeloma (MM) from Waldenstrom's macroglobulinemia (WM) is fraught with failure. WM can usually be distinguished from IgM MM by the lymphoplasmacytic versus pure plasmacytic morphology, absent versus present lytic bone lesions, and immunophenotypic findings. However, all these features have their own limitations; hence, it requires constant vigilance and periodic re-evaluation. Here we describe a case of a 70-year-old woman initially diagnosed as smoldering IgM MM, who eventually turned out to have WM.

Entities:  

Year:  2014        PMID: 25553130      PMCID: PMC4268296     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  14 in total

1.  Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy.

Authors:  Jun Wang; Lawrence M Weiss; Karen L Chang; Marilyn L Slovak; Karl Gaal; Stephen J Forman; Daniel A Arber
Journal:  Cancer       Date:  2002-03-01       Impact factor: 6.860

Review 2.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Roger G Owen; Steven P Treon; Ayad Al-Katib; Rafael Fonseca; Philip R Greipp; Mary L McMaster; Enrica Morra; Gerassimos A Pangalis; Jesus F San Miguel; Andrew R Branagan; Meletios A Dimopoulos
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

3.  IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.

Authors:  Steven R Schuster; Sundararajan Vincent Rajkumar; Angela Dispenzieri; William Morice; Alvaro Moreno Aspitia; Stephen Ansell; Robert Kyle; Joseph Mikhael
Journal:  Am J Hematol       Date:  2010-11       Impact factor: 10.047

Review 4.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

Authors:  S Vincent Rajkumar; Robert A Kyle; Francis K Buadi
Journal:  Mayo Clin Proc       Date:  2010-10       Impact factor: 7.616

5.  IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14).

Authors:  Sylvia Feyler; Sheila J M O'Connor; Andy C Rawstron; Chezhian Subash; Fiona M Ross; Guy Pratt; Mark T Drayson; John Ashcroft; Gordon Cook; Roger G Owen
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

6.  Phenotypic evolution of Waldenstrom's macroglobulinemia to extramedullary plasmacytoma.

Authors:  Qaiser Bashir; Choon-Kee Lee; Rodney W Stuart; Maxwell L Smith; John Ryder; Ricardo Gonzalez
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

7.  NCCN clinical practice guidelines in oncology: multiple myeloma.

Authors:  Kenneth C Anderson; Melissa Alsina; William Bensinger; J Sybil Biermann; Asher Chanan-Khan; Adam D Cohen; Steven Devine; Benjamin Djulbegovic; Cristina Gasparetto; Carol Ann Huff; Madan Jagasia; Bruno C Medeiros; Ruby Meredith; Noopur Raje; Jeffrey Schriber; Seema Singhal; George Somlo; Keith Stockerl-Goldstein; Guido Tricot; Julie M Vose; Donna Weber; Joachim Yahalom; Furhan Yunus
Journal:  J Natl Compr Canc Netw       Date:  2009-10       Impact factor: 11.908

Review 8.  [IgM myeloma: 6 cases and a review of the literature].

Authors:  A De Gramont; B Grosbois; J L Michaux; A M Peny; J P Pollet; N Smadja; M Krulik; J Debray; J F Bernard; M Monconduit
Journal:  Rev Med Interne       Date:  1990 Jan-Feb       Impact factor: 0.728

9.  Clinicopathological correlates of IgM paraproteinemias.

Authors:  R G Owen; L A Parapia; J Higginson; S A Misbah; J A Child; G J Morgan; A S Jack
Journal:  Clin Lymphoma       Date:  2000-06

10.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

View more
  2 in total

1.  Serum Free Light Chain Only Myeloma with Cytoplasmic IgM.

Authors:  Hideaki Ebana; Ken-Ichi Nakamura; Yoshihiro Nozawa; Ritsuko Seki; Masayuki Mita
Journal:  Case Rep Hematol       Date:  2014-06-17

2.  Case Report of IgM Multiple Myeloma: Diagnosing a Rare Hematologic Entity.

Authors:  Fernando Javier Bonilla-Valentín; Javier Cerra; William Cáceres-Perkins; Melissa Alsina
Journal:  Cancer Control       Date:  2018 Jan-Mar       Impact factor: 3.302

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.